Deprescribing of Diabetes Regimens in Long Term Care Residents with Alzheimer's

Not Applicable

• Conditions: Diabetes; Dementia; Hypoglycemia; Drug
• Interventions: Behavioral: STRIDE

• Registration Number: NCT05535478
• Lead Sponsor: Joslin Diabetes Center

Brief Summary

Objectives To 1) examine the ability of the STRIDE (Simplification of Treatment Regimens and Individualized Diabetes Education) educational program to increase deprescribing of high hypoglycemia risk glucose-lowering medications (HRMs) among long term care facility (LTCF) residents with ADRD, 2) assess key implementation constructs (secondary outcomes) of the STRIDE program, including acceptability, appropriateness, and feasibility, and 3) validate the primary HRM use outcome measure.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-08-26
• Study First Submitted QC: 2022-09-06
• Study First Posted: 2022-09-10
• Study Start: 2023-01-31
• Status Verified: 2024-12
• Last Update Submitted: 2025-03-03
• Last Update Posted: 2025-03-04
• Primary Completion: 2025-05-30
• Study Completion: 2025-05-30

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Clinical staff at the LTCF (MDs, PAs, NPs, clinical pharmacists) - (Targeted providers for STRIDE program)
• Clinical staff that participated in the STRIDE program (Providers doing stakeholder exit interviews)

Exclusion Criteria

• Consistent with the pragmatic nature of the trial, there are no exclusion criteria.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
STRIDE Intervention	STRIDE	Educational intervention for clinicians

Primary Outcome Measures

Name	Time	Method
Change in proportion of long term care facility (LTCF) residents with Alzheimer's disease adn related dementias (ADRD) and diabetes with high risk medications (HRM) use	Baseline vs 6 months	HRM use will include any sulfonylurea use (i.e., glyburide, glipizide, glimepiride, or chlorpropamide) and any insulin use.

Secondary Outcome Measures

Name	Time	Method
Acceptability of the STRIDE Educational Program	6 months	The extent to which the program is agreeable to LTCF staff- using the Acceptability of Intervention Measure (AIM)
Feasibility of the STRIDE Educational Program	6 months	The extent to which the program is practical at the LTCF level- using the Feasibility of Intervention Measure (FIM)
Appropriateness of the STRIDE Educational Program	6 months	The extent to which the program is suitable for a particular purpose, i.e., to improve the frequency at which LTCF staff attempt diabetes medication regimen deprescribing- using the Intervention Appropriateness Measure (IAM)

Trial Locations

Locations (1)

Joslin Diabetes Center; 🇺🇸 Boston, Massachusetts, United States